CJC-1295
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release growth hormone in a pulsatile, natural pattern. Often combined with Ipamorelin for synergistic effect.
Quick facts
- Half-life
- ~6–8 days (with DAC)
- Administration
- Subcutaneous injection
- Primary use
- Growth hormone stimulation
How it works
CJC-1295 binds to GHRH receptors on the pituitary gland, increasing the amplitude of natural growth hormone pulses. The DAC (Drug Affinity Complex) version extends its half-life significantly by binding to albumin in the bloodstream.
Reported benefits
- Increased growth hormone and IGF-1 levels
- Improved body composition (lean mass / fat ratio)
- Enhanced recovery and sleep quality
- Anti-aging effects on skin and connective tissue
Typical dosing protocol
Dosing
CJC-1295 DAC: 1–2 mg per week. Without DAC: 100–200 mcg per injection, 2–3x daily
Cycle length
8–12 weeks, followed by a break
Dosing information is for educational reference only. Individual needs vary. Always consult a healthcare professional.
Safety & considerations
Not approved for human use in the UK. May cause water retention, tingling, or headaches. Not suitable for those with active cancer. Consult a healthcare professional before use.
Tags
Important: All content is for informational purposes only. Not medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.